Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal

Raloxifene hydrochloride (RLX) is a selective estrogen-receptor modulator for treatment of osteoporosis and prevention of breast and endometrial cancer. By virtue of extensive presystemic clearance, RLX bioavailability is only 2%. The current study aimed to tailor and characterize RLX-loaded self-na...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsheikh, Manal A, Elnaggar, Yosra SR, Gohar, Eman Y, Abdallah, Ossama Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414224/
https://www.ncbi.nlm.nih.gov/pubmed/22888234
http://dx.doi.org/10.2147/IJN.S33186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414224/
https://www.ncbi.nlm.nih.gov/pubmed/22888234
http://dx.doi.org/10.2147/IJN.S33186

Ejemplares similares